RVXCF
Price:
$0.04
Market Cap:
$11.23M
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.[Read more]
Industry
Biotechnology
IPO Date
2009-02-13
Stock Exchange
PNK
Ticker
RVXCF
According to Resverlogix Corp.’s latest financial reports and current stock price. The company's current Enterprise Value is 17.90M. This represents a change of -19.97% compared to the average of 22.37M of the last 4 quarters.
The mean historical Enterprise Value of Resverlogix Corp. over the last ten years is 187.17M. The current 17.90M Enterprise Value has changed 856.50% with respect to the historical average. Over the past ten years (40 quarters), RVXCF's Enterprise Value was at its highest in in the October 2018 quarter at 477.65M. The Enterprise Value was at its lowest in in the April 2018 quarter at 587.00K.
Average
187.17M
Median
138.15M
Minimum
32.97M
Maximum
568.34M
Discovering the peaks and valleys of Resverlogix Corp. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 311.24%
Maximum Annual Enterprise Value = 568.34M
Minimum Annual Increase = -75.70%
Minimum Annual Enterprise Value = 32.97M
Year | Enterprise Value | Change |
---|---|---|
2022 | 32.97M | -67.98% |
2021 | 102.98M | -25.43% |
2020 | 138.10M | -75.70% |
2019 | 568.34M | 311.24% |
2018 | 138.20M | -30.55% |
2017 | 198.99M | 45.53% |
2016 | 136.74M | -38.07% |
2015 | 220.80M | 190.68% |
2014 | 75.96M | -70.63% |
2013 | 258.63M | 179.50% |
The current Enterprise Value of Resverlogix Corp. (RVXCF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
91.35M
5-year avg
196.12M
10-year avg
187.17M
Resverlogix Corp.’s Enterprise Value is less than Cellectis S.A. (115.55M), greater than Biotron Limited (16.98M), less than Small Pharma Inc. (34.51M), less than Covalon Technologies Ltd. (93.17M), greater than Bioasis Technologies Inc. (397.14K), less than Fennec Pharmaceuticals Inc. (105.60M), less than Biohaven Pharmaceutical Holding Company Ltd. (4.54B), less than ImmunityBio, Inc. (4.07B), less than Cadrenal Therapeutics, Inc. Common Stock (20.50M), less than Foghorn Therapeutics Inc. (417.24M), greater than Comera Life Sciences Holdings, Inc. (-1587053.00), less than Coya Therapeutics, Inc. (0), less than NewAmsterdam Pharma Company N.V. (77.54M), less than Centessa Pharmaceuticals plc (1.37B), less than Eliem Therapeutics, Inc. (1.75B), less than Inhibrx Biosciences, Inc. (119.64M), greater than Merrimack Pharmaceuticals, Inc. (9.32M), greater than Celcuity Inc. (-10189682.00), less than Enliven Therapeutics, Inc. (574.33M), less than null (1.10B),
Company | Enterprise Value | Market cap |
---|---|---|
115.55M | $183.12M | |
16.98M | $11.30M | |
34.51M | $37.51M | |
93.17M | $72.60M | |
397.14K | $284.08K | |
105.60M | $145.92M | |
4.54B | $4.60B | |
4.07B | $3.55B | |
20.50M | $24.86M | |
417.24M | $435.85M | |
-1587053.00 | $9.22K | |
0 | $108.60M | |
77.54M | $1.87B | |
1.37B | $2.06B | |
1.75B | $342.68M | |
119.64M | $203.82M | |
9.32M | $223.97M | |
-10189682.00 | $489.74M | |
574.33M | $1.20B | |
1.10B | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Resverlogix Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Resverlogix Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Resverlogix Corp.'s Enterprise Value?
What is the highest Enterprise Value for Resverlogix Corp. (RVXCF)?
What is the 3-year average Enterprise Value for Resverlogix Corp. (RVXCF)?
What is the 5-year average Enterprise Value for Resverlogix Corp. (RVXCF)?
How does the current Enterprise Value for Resverlogix Corp. (RVXCF) compare to its historical average?